Clinical Trial Update: 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating 3-AP and gemcitabine in recurrent, unresectable, or metastatic pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 3-AP
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED